China’s role in U.S. pharma supply chain problems

    China’s role in U.S. pharma supply chain problems

    First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a…

    Read More
    STAT+

      RFK Jr. peptides, Sanofi insulin, CRISPR-related death: Readout

      Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, a win for RFK Jr., as an FDA panel narrowly voted in favor of allowing compounding pharmacies to produce certain unregulated peptides. Also, in heart-wrenching detail, Science writes of the six-year-old girl who died…

      Read More
      Technicians assemble humanoid robots at the Lingyi iTech Guangdong Co. Embodied Intelligence Super Factory facility in Beijing, China, on 29 May 2026.

        Is China a threat, or just out-engineering everyone?

        Add ThinkChina as a preferred source Technicians assemble humanoid robots at the Lingyi iTech Guangdong Co. Embodied Intelligence Super Factory facility in Beijing, China, on 29 May 2026. (Qilai Shen/Bloomberg) The eminent scientist and sinologist Joseph Needham famously formulated two questions on Chinese science and technology (S&T) in his 1969 book The Great Titration: Science and…

        Read More
        Attendees look at the China booth at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, US, on 23 June 2026.

          US’s biotech scrutiny tests China’s drugmakers abroad

          Add ThinkChina as a preferred source Attendees look at the China booth at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, US, on 23 June 2026. (Mike Blake/Reuters) (By Caixin journalist Chen Xi) US lawmakers’ push to scrutinise biotechnology ties with China is unsettling expectations for Chinese…

          Read More
          STAT+

            China, Shanghai, AI hair growth drug, Eli Lilly: Readout Newsletter

            Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi from BIO! I’m sitting in the frigid media room here next to STAT’s Brittany Trang, who is writing something scintillating about artificial intelligence.  Today, we’ve got Lilly chasing aesthetics with a AI-designed experimental hair loss…

            Read More
            China’s investment in innovation is fostering scientific and technological advances. Jin Liwang/Xinhua via Getty Images

              China surpasses US in research spending

              China’s rapid rise in science has hit a milestone. The country’s investment in research and development has reached parity with – and by purchasing power measures has surpassed – that of the United States, according to a March 2026 report from the Organisation for Economic Co-operation and Development. Both nations have crossed the US$1 trillion…

              Read More
              China Just Surpassed the US in Research Spending and it Could Cost America a Trillion Dollars Over the Next Decade

                China Just Surpassed the US in Research Spending and it Could Cost America a Trillion Dollars Over the Next Decade

                Credit: ZME Science. China’s rapid rise in science has hit a milestone. The country’s investment in research and development has reached parity with – and by purchasing power measures has surpassed – that of the United States, according to a March 2026 report from the Organisation for Economic Co-operation and Development. Both nations have crossed…

                Read More
                STAT+

                  China’s rapid ascent is reshaping drug development

                  Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The NIH’s foreign subaward crackdown is scrambling global collaborations, while China’s rapid ascent is reshaping drug development. Meanwhile, Wave Life Sciences sheds half its value on underwhelming obesity results. Also, breaking: I’m adopting a rogue…

                  Read More